AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
ACB   12.18 (-0.73%)
DIS   114.43 (+2.01%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
ACB   12.18 (-0.73%)
DIS   114.43 (+2.01%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
ACB   12.18 (-0.73%)
DIS   114.43 (+2.01%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
ACB   12.18 (-0.73%)
DIS   114.43 (+2.01%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
Log in

NASDAQ:EYESSecond Sight Medical Products Stock Price, Forecast & News

$0.94
-0.03 (-2.69 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.91
Now: $0.94
$0.99
50-Day Range
$0.91
MA: $1.03
$1.54
52-Week Range
$0.71
Now: $0.94
$8.96
Volume400,055 shs
Average Volume528,202 shs
Market Capitalization$14.65 million
P/E RatioN/A
Dividend YieldN/A
Beta2.43
Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. It also offers Argus II Retinal Prosthesis System for treating retinitis pigmentosa. The company was founded in 1998 and is headquartered in Sylmar, California.
Read More
Second Sight Medical Products logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.51 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYES
CUSIPN/A
Phone818-833-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.38 million
Book Value$0.47 per share

Profitability

Net Income$-33,590,000.00
Net Margins-994.14%

Miscellaneous

Employees123
Market Cap$14.65 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive EYES News and Ratings via Email

Sign-up to receive the latest news and ratings for EYES and its competitors with MarketBeat's FREE daily newsletter.

Second Sight Medical Products (NASDAQ:EYES) Frequently Asked Questions

How has Second Sight Medical Products' stock been impacted by COVID-19 (Coronavirus)?

Second Sight Medical Products' stock was trading at $3.53 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EYES stock has decreased by 73.5% and is now trading at $0.9354. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Second Sight Medical Products?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Second Sight Medical Products in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Second Sight Medical Products.

When is Second Sight Medical Products' next earnings date?

Second Sight Medical Products is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Second Sight Medical Products.

How were Second Sight Medical Products' earnings last quarter?

Second Sight Medical Products Inc (NASDAQ:EYES) posted its quarterly earnings results on Monday, June, 29th. The medical device company reported ($0.57) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.16. Second Sight Medical Products had a negative return on equity of 308.26% and a negative net margin of 994.14%. View Second Sight Medical Products' earnings history.

What price target have analysts set for EYES?

2 Wall Street analysts have issued 1-year price objectives for Second Sight Medical Products' stock. Their forecasts range from $2.00 to $2.50. On average, they anticipate Second Sight Medical Products' share price to reach $2.25 in the next year. This suggests a possible upside of 140.5% from the stock's current price. View analysts' price targets for Second Sight Medical Products.

Has Second Sight Medical Products been receiving favorable news coverage?

Press coverage about EYES stock has been trending negative on Monday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Second Sight Medical Products earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news articles about the medical device company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Second Sight Medical Products.

Are investors shorting Second Sight Medical Products?

Second Sight Medical Products saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 628,700 shares, a decline of 11.2% from the June 15th total of 708,200 shares. Based on an average daily trading volume, of 947,100 shares, the short-interest ratio is currently 0.7 days. Approximately 5.0% of the company's shares are short sold. View Second Sight Medical Products' Current Options Chain.

Who are some of Second Sight Medical Products' key competitors?

What other stocks do shareholders of Second Sight Medical Products own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), Cara Therapeutics (CARA), Shopify (SHOP), Opko Health (OPK), Canopy Growth (CGC), VBI Vaccines (VBIV), Corbus Pharmaceuticals (CRBP), TransEnterix (TRXC) and Plug Power (PLUG).

Who are Second Sight Medical Products' key executives?

Second Sight Medical Products' management team includes the following people:
  • Mr. Jonathan Will McGuire, CEO, Pres & Director (Age 56)
  • Mr. John T. Blake, CFO & Corp. Sec. (Age 43)
  • Mr. William Patrick Ryan, Chief Operating Officer (Age 58)
  • Gunnar Bjorg, Founder
  • Mr. Stephen D. Okland Jr., Chief Commercial Officer (Age 55)

When did Second Sight Medical Products IPO?

(EYES) raised $32 million in an IPO on Wednesday, November 19th 2014. The company issued 3,500,000 shares at a price of $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO.

What is Second Sight Medical Products' stock symbol?

Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."

How do I buy shares of Second Sight Medical Products?

Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Second Sight Medical Products' stock price today?

One share of EYES stock can currently be purchased for approximately $0.94.

How big of a company is Second Sight Medical Products?

Second Sight Medical Products has a market capitalization of $14.65 million and generates $3.38 million in revenue each year. The medical device company earns $-33,590,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Second Sight Medical Products employs 123 workers across the globe.

What is Second Sight Medical Products' official website?

The official website for Second Sight Medical Products is www.secondsight.com.

How can I contact Second Sight Medical Products?

Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected]

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.